We are focused on developing pharmacological approaches to reduce disease progression and mortality in PAH and CKD.
2017- Founded
2019- SBIR Phase I Award
A Novel Therapeutic DDAH for the Treatment of Acute Kidney Injury
2020- SBIR Phase I Award
Preclinical Development of a Novel Disease Modifying Therapy for Pulmonary Arterial Hypertension
2020- NHILB Catalyze Award
Synthesis New Compounds and Lead Optimization of Small Molecule DDAH-1 Modulator
2021- BARDA Blue Knight QuickFire Winner
2024- SBIR Phase II Award
Development of a Novel Disease Modifying Oral Therapy for Pulmonary Arterial Hypertension
> $4 million grants awarded
Selective Aryl Hydrocarbon Receptor Modulators (SAhRM)
AhR is known to play important pathological roles in inflammatory and fibrotic diseases [1,2]. AhR activation has been found essential for PAH progression in humans and animal models [3].
Vasculonics is developing novel selective aryl hydrocarbon receptor modulators (SAhRM) and suppressor of vascular toxin asymmetric dimethyl arginine (ADMA) the critical pathological mechanisms of PAH.
VN-1032 is a novel SAhRM with major impact on the mechanisms of inflammation, oxidative stress and fibrosis.
VN-1032 has demonstrated disease modifying efficacy in a PAH and CKD disease progression models when delivered as an oral formulation.
1. Beischlag TV., et al. Crit. Rev. Eukaryot. Gene Expr. 2008, 18 (3), 207–250.
2. Perdew GH., et al. Int. J. Mol. Sci. 2023, 24 (6).
3. Masaki T., et al. Proc. Natl. Acad. Sci. U. S. A. 2021, 118 (11), e2023899118.
VN-1032 reduced (A) kidney, (B) cardiac fibrosis in rat model of CKD.
VN-1032 promotes (A) remodeling of lung vessels, (B) reduced lung inflammation in Sugen-Hypoxia PAH model.
Therapeutic Extracorporeal Device (TED)
A breakthrough device for organ protection and improving the survival of sepsis patients. Targeting host response mechanisms of vascular damage, inflammation, and mitochondrial dysfunction.
Blood levels of the uremic toxin, asymmetric dimethylarginine (ADMA), are strongly associated with mortality in sepsis, renal failure, and cardiovascular and renal disease patients [1,2].
Vasculonics is the first to develop ADMA lowering technology, generating pharmacological POC for organ protection in preclinical models and aiming for clinical testing in sepsis patients.
This innovative platform is particularly relevant for enhancing warfighter resilience, as it has the potential to significantly reduce morbidity and mortality associated with trauma and traumatic brain injury (TBI) sustained in combat situations, ultimately improving outcomes for soldiers and supporting their recovery in the field.
1. Winkler MS., et al. Crit. Care 2018, 22 (1), 216.
2. Van Wijk XMR., et al. J. Appl. Lab. Med. 2021, 6 (3), 592-605.
Vasculonics’ differentiating technology targets microvascular dysfunction, organ damage, and death in sepsis.
Engineering TED into Prismaflex system and selectively eliminated uremic toxin in porcine model. [Lee Y., et al. Blood Purif. 2022, 51 (11), 889–898.]
1800 North Capitol Avenue, Noyes Pavilion 5th Floor, E504C, Indianapolis, Indiana 46202, United States
Copyright © 2024 Vasculonics - All Rights Reserved.